Clinical Trial

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-20.
Trial Details
NCT Number NCT06897527
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms, Endometrial
Enrollment 100 participants
Start Date 2025-07-15
Primary Completion 2027-01-13 (estimated)
Study Completion 2027-01-13 (estimated)
Updated on ClinicalTrials.gov 2025-07-08